![](/statics/home_en/images/loading-1.png)
Search
# Popular search #
# Popular search #
Stock Code
603087.SHGan & Lee Pharmaceuticals’ Bi-weekly(twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
Gan & Lee Pharmaceuticals Successfully Shines at the American Diabetes Association's 84th Scientific Sessions
Gan & Lee Pharmaceuticals Announces Received Approval of Local-filling Insulin Aspart 30 Injection in Bangladesh
Gan & Lee Pharmaceuticals Shines at the 22nd CPHI China
Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions
Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions
To be a world-class pharmaceutical company with focus on global business development
Registered in 20 countries
Products launched in 18 countries
Clinical trials conducted in 12 countries
Registered in 20 countries
Products launched in 18 countries
Clinical trials conducted in 12 countries
This website uses cookies to give users like yourself the best possible content and experience. For more information about your choices regarding cookies, please review our Privacy Policy .
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.